Newsroom
Contact us
FAQ
Íslenska
  • Company
  • For investors
  • Biosimilars
  • Corporate Sustainability
  • Careers
Company Announcement
22 October 2025

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

REYKJAVIK, ICELAND (OCTOBER 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today...
Company Announcement
06 October 2025

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

LONDON, UK and REYKJAVIK, ICELAND (OCTOBER 6, 2025) — Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital,...
Company Announcement
22 September 2025

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®

REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today...
Company Announcement
22 September 2025

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Company Announcement
19 September 2025

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

REYKJAVIK, ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today...
Company Announcement
04 September 2025

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

REYKJAVIK, Iceland, June 4, 2025 - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its...
Company Announcement
21 August 2025

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration...
Company Announcement
20 August 2025

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced...
Financial Reports
13 August 2025

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flowsContinued expansion of commercial partnerships for...
Company Announcement
06 August 2025

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

REYKJAVIK, ICELAND (August 6, 2025) – Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today...
1…67…32
  • About Us
  • Media Center
  • Careers
  • Newsroom
  • Contact us
  • Terms of Use
  • Privacy Policy
  • Cookie Policy

Alvotech 2025. All rights reserved.